# Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

> **NCT06809426** · NA · COMPLETED · sponsor: **Affiliated Hospital of Jiangnan University** · enrollment: 13 (actual)

## Conditions studied

- PSMA PET-Positive Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** 177Lu-LNC1011

## Key facts

- **NCT ID:** NCT06809426
- **Lead sponsor:** Affiliated Hospital of Jiangnan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-21
- **Primary completion:** 2024-10-14
- **Final completion:** 2024-10-24
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06809426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06809426, "Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06809426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*